Anavex Life Sciences Corp. (NASDAQ:AVXL) CEO Sells $374,971.80 in Stock

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) CEO Christopher U. Missling sold 73,380 shares of Anavex Life Sciences stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $5.11, for a total transaction of $374,971.80. Following the transaction, the chief executive officer now directly owns 1,250,210 shares of the company's stock, valued at $6,388,573.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Anavex Life Sciences Trading Down 1.4 %

Shares of NASDAQ:AVXL traded down $0.07 during trading on Monday, hitting $5.02. 819,532 shares of the company's stock were exchanged, compared to its average volume of 1,476,551. Anavex Life Sciences Corp. has a 1-year low of $4.48 and a 1-year high of $10.45. The firm has a 50-day moving average price of $5.45 and a two-hundred day moving average price of $6.34. The firm has a market cap of $412.19 million, a P/E ratio of -9.30 and a beta of 0.56.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. As a group, research analysts predict that Anavex Life Sciences Corp. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Anavex Life Sciences by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 4,360,648 shares of the biotechnology company's stock worth $40,598,000 after buying an additional 115,304 shares during the period. Goldman Sachs Group Inc. boosted its stake in Anavex Life Sciences by 20.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 266,573 shares of the biotechnology company's stock worth $2,482,000 after acquiring an additional 45,556 shares during the last quarter. Virtu Financial LLC bought a new position in Anavex Life Sciences during the 4th quarter worth approximately $202,000. Barclays PLC boosted its stake in Anavex Life Sciences by 31.0% during the 4th quarter. Barclays PLC now owns 210,430 shares of the biotechnology company's stock worth $1,959,000 after acquiring an additional 49,853 shares during the last quarter. Finally, Nwam LLC boosted its stake in Anavex Life Sciences by 10.7% during the 4th quarter. Nwam LLC now owns 798,293 shares of the biotechnology company's stock worth $7,432,000 after acquiring an additional 77,303 shares during the last quarter. Institutional investors and hedge funds own 31.55% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on shares of Anavex Life Sciences from $54.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, January 3rd.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.